loe-exposure
Server Details
Drug patent expiries ranked by the Medicare Part D spending exposed to them
- Status
- Healthy
- Uptime
- 100.0% over the last 24 hours
- Last Tested
- Transport
- Streamable HTTP · MCP 2024-11-05
- URL
- ChatGPT
- –
- Claude
- –
TDQS
Scored across 1 tool
With only a single tool, there is no possibility of overlap or confusion with other tools. The tool's purpose is unambiguous and clearly stated.
The lone tool name follows a clear, descriptive noun-based pattern. With no other tools to compare against, naming inconsistency is not a concern.
The server is scoped to a single, highly specific analytical task, so one tool is arguably appropriate. However, it is on the thin side and slightly under the typical useful range for a server.
The tool covers the core advertised functionality of ranking LOE exposure by Medicare Part D spending. It lacks additional capabilities such as filtering by drug, date range, or drilling into individual drug details, which are notable gaps for realistic use.
Available Tools
1 toolloss_of_exclusivity_exposureAInspect
Rank upcoming FDA Orange Book patent and exclusivity expiries BY the gross Medicare Part D spending exposed to them, with marketed-generic status for each ranked drug resolved from live CMS NADAC price evidence. Answers which expiries matter, not merely which come first. Reports EXPOSURE, never forecast savings. Spending is gross of manufacturer rebates. Orange Book small molecules only, so biologics — among the largest Part D line items — are excluded, and the headline total must not be read as spending that will "go generic".
Inputs: limit, window.
Tool Schema Changelog
Recent tool additions, removals, and schema changes observed during successful MCP inspections.
Loading tool schema changelog…
Related MCP Connectors
CMS Medicare drug price negotiation: the Maximum Fair Price (MFP) for every drug CMS has selected…
US drug price benchmarks — what a pharmacy PAYS and what Medicare PAYS OUT.
Whether a drug has a marketed generic today, and when its Orange Book protections lapse
CMS Medicare Part D drug spending and prescriber data. 2024 quarterly data.
Related MCP Servers
- AlicenseNot gradedqualityCmaintenanceQueries US prescription drug use by medical condition from AHRQ's Medical Expenditure Panel Survey — which drugs Americans take for a given condition, what a drug is prescribed for, and national volume, spending and out-of-pocket share for individual drugs or the top drugs of a year. Every response carries sample sizes and reliability flags so estimates are treated as rough magnitude and ranking rather than precise counts.86 npmMIT
- AlicenseNot gradedqualityDmaintenanceProvides unified access to drug formulary data from US ACA marketplace health insurance plans, enabling drug search, coverage details, restriction info, and plan comparison across thousands of plans.MIT
- AlicenseNot gradedqualityCmaintenanceEnables searching and analyzing FDA Orange Book data for drug competition, including products, patents, and exclusivities.8 npmMIT
- AlicenseNot gradedqualityCmaintenancePharmaceutical R\&D Pipeline Intelligence for AI Agents — Clinical trials, FDA approvals, drug information & publications in one MCP server.5MIT
Glama MCP Gateway
Add one secure layer between your agents and this server.